Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol

Table 3 Management of patients in the experimental group on day 2 follow-up visit

Temperature	CRP	Treatment plan
< 38 °C	≤ 10 mg/L	Continue with prednisolone at 2 mg/kg/day no additional treatment required [reassess on day 5]; reduce aspirin to 3–5 mg/kg/day when afebrile for at least 48 h and continue for at least 21 days after resolution of fever^a
< 38 °C	> 10 mg/L but ≤ 50% of baseline	Continue with prednisolone at 2 mg/kg/day no additional treatment required [reassess on day 5]; reduce aspirin to 3–5 mg/kg/day when afebrile for at least 48 h and continue for at least 21 days after resolution of fever^a
< 38 °C	> 10 mg/L and still > 50% of baseline	Continue with prednisolone at 2 mg/kg/day and administer second dose of IVIG; reduce aspirin to 3–5 mg/kg/day when afebrile for at least 48 h and continue for at least 21 days after resolution of fever^a
≥ 38 °C	≤ 10 mg/L	Continue with prednisolone at 2 mg/kg and administer second dose of IVIG; continue with aspirin at 40 mg/kg/day until afebrile
≥ 38 °C	≤ 10 mg/L but ≤ 50% of baseline	Continue with prednisolone at 2 mg/kg/day and administer second dose of IVIG; continue with aspirin at 40 mg/kg/day until afebrile
≥ 38 °C	≤ 10 mg/L and still > 50% of baseline	Continue with prednisolone at 2 mg/kg/day and administer second dose of IVIG; continue with aspirin at 40 mg/kg/day until afebrile

ISSN: 1745-6215